Megan Tooley, Cardiovascular Roundtable
For those of you who missed it, I wanted to share a recent blog post by our colleagues at the Advisory Board’s Technology Insights program, “TAVR Poised for Further Market Expansion,” which provides an overview of the latest research on transcatheter valves presented at the 2013 American College of Cardiology Scientific Sessions in San Francisco.
TAVR highlights from ACC 2013
Nicole MacMillan, Cardiovascular Roundtable
A recent study presented at the 2012 EuroPCR conference in Paris has demonstrated promising evidence in favor of CardioKinetix’s “Parachute” device, designed to segment off part of the left ventricular wall in heart failure patients. This was the first-in-human trial for the parachute device. Researchers found it significantly improved symptoms of heart failure, decreased ventricular volume, and reduced death and hospitalization for heart failure one year post-implantation.
Parachute device a promising intervention for heart failure
Off-pump coronary artery bypass graft (CABG) surgery is associated with an increased risk of mortality as compared to traditional on-pump CABG, according to a new report published in the Cochrane Database of Systematic Reviews. Furthermore, study authors suggest that past studies that favor the off-pump approach may have been influenced by patient-selection or industry bias.
Higher risk of death with off-pump CABG, new research suggests